TGFB1 and diabetic kidney disease: TGF‐β1 monoclonal antibody (mAb): Inhibiting TGF‐β1 activity with a specific, humanized, neutralizing mAb was explored in a placebo‐controlled phase II trial among patients with diabetic nephropathy to attenuate progressive renal fibrosis and loss of renal function.